Skip to main content
BAX logo

BAX · Baxter International Inc

Track BAX — free
$25.39 +0.00 (+0.00%) At close · Nov 20
Market Cap
$13.14B
Shares
517.35M
Volume · Nov 20 4.32M Avg daily vol (3M) 6.35M

Price & Indicators

 

Key stats

Close
$25.39
Fri 20 Nov
Open
$25.45
Fri 20 Nov
Average volume, 30 days
6.5M
shares a session
Short interest
23.7M
4.6% of shares · 3.0 days to cover
Day range
$24.85$26.09
Open $25.45 Close $25.39
52-week closing range
$15.80$28.35
Close $25.39 10.4% under the high
Short volume, last session
48%
Last earnings
Oct 29, 2026
Latest filing
10-Q · Oct 29
Price history
Jan 2020 to Nov 2026

Up next

Feb 11, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 19
Current report 8-K
Raises 2026 organic sales guidance to +3-4%

Baxter raised its full-year 2026 organic sales guidance to +3-4% and reported year-to-date free cash flow of $705 million. It also completed a $600 million cash tender offer that retired $864 million of debt.

Regulation FD disclosure
3 source passages
Raised full-year 2026 organic sales guidance2 to +3-4% Year-to-date free cash flow3 of $705 million reflects our focus on improving working capital and strengthening cash flow generation Completed a $600 million cash tender offer, retiring $864 million of debt and accelerating deleveraging while supporting our investment-grade credit objectives Open the document at this passage
Oct 29
Earnings call
Raises full-year organic sales growth outlook to 3% to 4%

Third-quarter global sales rose 5% to approximately $3 billion on both reported and organic bases, and adjusted earnings were $0.58 per diluted share. The company raised its full-year organic sales growth outlook to 3% to 4% from 2% to 3%, and its adjusted earnings per diluted share outlook to $2.05 to $2.15.

4 source passages
Third quarter global sales totaled approximately $3 billion, an increase of 5% on both a reported and organic basis. Adjusted earnings were $0.58 for diluted share. We are raising our full-year outlook for organic sales growth to a range of 3% to 4%, from 2% to 3%. We're also raising the bottom end of our outlook for adjusted earnings per diluted share to $2.05 to $2.15 Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter net income $294 million, $0.57 per diluted share

Baxter International reported net income attributable to Baxter stockholders of $294 million, or $0.57 per diluted share, for the three months ended September 30, 2026, compared with $(46) million, or $(0.09) per diluted share, a year earlier. Results included a $253 million gain on early extinguishment of debt. The company expects no meaningful Novum LVP sales while shipment and installation holds remain in effect.

Revenue $2.98B ▲ 5.0% Net income $294M Diluted EPS $0.57
Read from the MD&A section
4 source passages
Net income (loss) attributable to Baxter stockholders for the three months ended September 30, 2026 was $294 million, or $0.57 per diluted share, compared to $(46) million, or $(0.09) per diluted share for the three months ended September 30, 2025. Our results for the third quarter and the first nine months of 2026 included a gain of $253 million on the early extinguishment of debt. In July 2025, we elected to temporarily stop distributing and installing the Novum LVP in the U.S. and Canada, except in the case of medical necessity. As a result, we expect no meaningful sales of Novum LVP while these holds are in effect. Open the document at this passage
Oct 29
Current report 8-K Events of Oct 28
Raises 2026 Outlook After Third-Quarter Sales Rise 5%

Baxter reported third-quarter sales of approximately $2.98 billion, up 5% on both a reported and organic basis, with U.S. GAAP diluted earnings per share of $0.57. The company raised its full-year 2026 reported sales growth outlook to 4% to 5%, from 3% to 4%. The board declared a quarterly cash dividend of $0.01 per share, payable January 4, 2027.

Financial results, Other events Read from the first part of this long document
5 source passages
Third-quarter sales of $2.98 billion increased 5% on both a reported and organic basis,1,2 reflecting growth in all segments and divisions Third-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.57; adjusted diluted EPS of $0.581 Reported sales growth from continuing operations: 4% to 5% (previously 3% to 4%) Effective October 28, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on January 4, 2027, to stockholders of record as of November 27, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$11.61B
Trailing 12 months
Net income (TTM)
−$723.00M
Trailing 12 months
Revenue growth YoY
+5.0%
Year over year
Operating margin
-1.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$7.51B
Latest balance sheet
Dividend yield
0.2%
Trailing 12 months
Shares change YoY
+1.2%
Year over year · more shares
Price change (1Y)
+45.8%
Trailing year
Short interest
4.6%
Latest settlement · 3.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026
Q2 FY26

TL;DR. Baxter reported Q2 sales of $2.96B (up 5% reported and organic), beating expectations and driven by broad-based growth including a $75M IEEPA tariff refund not in prior guidance; the company raised full-year 2026 reported sales growth to 3-4%, organic sales to 2-3%, and adjusted EPS to $1.95-$2.15 from $1.85-$2.05.

Bullish
  • + Raised full-year 2026 adjusted EPS guidance to $1.95-$2.15 from $1.85-$2.05, reflecting the Q2 tariff refund
  • + Advanced Surgery sales grew 12% to $331M on continued strong global demand for hemostats and sealants
Bearish
  • − Q2 adjusted EPS of $0.56 declined 5% YoY due to higher-cost inventory roll-through and unfavorable prior-year comparison
  • − MPT segment adjusted operating margin fell 350 bps to 19.3% on higher manufacturing costs and Section 232 tariff impact
  • − Adjusted gross margin contracted 210 bps to 38.6% and adjusted operating margin fell 90 bps to 14.2%
  • − Novum IQ LVP remains on shipment and installation hold, pressuring Infusion Systems sales and creating customer uncertainty
  • − Supply constraints on injectables from a contract manufacturer and softness in pre-mixed products continue to weigh on results

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Moderate
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +17%
above
Price vs 50-day avg +3%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 76%
mid-range
Momentum
relative strength
Very Strong
1-month return 0%
trailing
6-month return +36%
trailing
YTD return +33%
this year
Relative strength +45%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $25 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +123 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.58% of shares out · ▼ -0.4% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
747 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Weak
Revenue growth +6%
Y/Y
Gross margin 30%
contracting
EPS growth −47%
Y/Y
Buyback $1.3B
remaining
Balance sheet $7.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 42%
annualized · 1-yr
Max drawdown −29%
past year
ATR 3.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 8
Latest guidance · from the 8-K filed Oct 29, 2026
full-year 2026
Reported sales growth from continuing operations 4% – 5%
Adjusted earnings from continuing operations per diluted share Raised $2.05 – $2.15
Jul 30, 2026 $1.95 – $2.15 changed to Oct 29, 2026 $2.05 – $2.15
FY 2026
Sales growth - U.S. GAAP Raised 4% – 5%
Jul 30, 2026 3% – 4% changed to Oct 29, 2026 4% – 5%
Previous outlook earlier release · from the 8-K filed Jul 30, 2026

Still-open targets the latest release did not restate under the same label.

Organic sales growth · FY 2026 2% – 3%
Guided vs delivered · last 8 settled
U.S. GAAP earnings per diluted share full-year 2023
guided $1.16 – $1.31
$5.23 Beat +323.5%
U.S. GAAP earnings per diluted share second-quarter 2023
guided $0.18 – $0.20
$-0.28 Miss −247.4%
U.S. GAAP earnings per diluted share first-quarter 2023
guided $0.14 – $0.18
$0.09 Miss −43.8%
U.S. GAAP earnings (loss) per diluted share full-year 2022
guided $-4.52 – $-4.45
$-4.83 Miss −7.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+17% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
76% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $25 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +123 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.58% of shares out · ▼ -0.4% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
747 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $16 Now $25 · 76% Range high $28
vs 200-day avg +17% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Organic sales growth non-GAAP 5% Three Months Ended June 30, 2026 filing —
Segment operating income - Healthcare Systems & Technologies $163M Three Months Ended June 30, 2026 filing —
Segment operating income - Medical Products & Therapies $400M Three Months Ended June 30, 2026 filing —
Special items impact on net income (loss) attributable to Baxter stockholders non-GAAP $155M Three Months Ended June 30, 2026 filing —
Special items impact on net income (loss) from continuing operations non-GAAP $155M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BAX
Baxter International Inc
this stock
$13.14B +32.9% +5.7% — 4.6%
ISRG
Intuitive Surgical Inc
$138.33B -29.5% +20.5% 48.4 2.0%
BDX
Becton Dickinson & Co
$57.96B — +8.2% 94.2 3.0%
MDLN
Medline Inc.
$48.72B -11.8% +11.5% — 2.9%
ALC
Alcon Inc
$35.70B -5.7% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
747
% held
100.6%
Net QoQ
-36.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
539
View
Short & Settlement
Short Interest Falling
Shares short
23.7M
Days to cover
3.0d
Change
-90.7K sh
View
Short Volume
Short vol %
48%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
10.8K
Value
$268.4K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
37.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Oct 31, 2025
View
Financials
Financials
Revenue (FY)
$11.2B
Net income (FY)
$-957.0M
EPS diluted
$-1.87
View
Buybacks
Remaining
$1.3B
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
26

Baxter raised its full-year 2026 organic sales guidance to +3-4% and reported year-to-date free cash flow of $705 million. It also completed a $600 million cash tender offer that retired $864 million of debt.

View
Proposed Sales
Value
$645.2K
Shares
36.3K
Filed
May 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Baxter Reports Third-Quarter 2026…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
BAX -1.6% +0.4% +35.9% +10.4% +32.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +6.9% +9.6% +45.1% +19.1% +31.7%

Capital returns

Latest dividend
$0.01 / share · ex Aug 28, 2026
Declared · upcoming
$0.01 / share · ex Nov 27, 2026
Cut 94.1%
Paid (TTM)
$0.04 / share · 4 payouts
Dividend yield (TTM, derived)
0.16%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$1.30B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 10456 CUSIP 071813109 13F (30d) 728 filings 635 filers Visit website Investor relations